Effects of enzyme-replacement therapy in patients with Anderson–Fabry disease: a prospective long-term cardiac magnetic resonance imaging study

Abstract

Long-term therapy with agalsidase beta at 1 mg/kg every 2 weeks was effective in significantly reducing LV hypertrophy, improving overall cardiac performance and ameliorating clinical symptoms in patients with Anderson-Fabry disease.